The difference was largely the result of differences in patients with shock ( talactoferrin , @/@ -LSB- @ % -RSB- vs placebo , @/@ -LSB- @ % -RSB- ; p = @ ) ; no mortality difference was seen in patients without shock ( talactoferrin , @/@ -LSB- @ % -RSB- vs placebo , @/@ -LSB- @ % -RSB- ; p = @ ) .